Certain antibodies targeting LRP-1’s CR9 domain have been proposed to prevent agLDL uptake and foam cell formation, suggesting LRP-1 as a potential target for atherosclerosis treatment (J. Chen et al., 2021). Here, LRP1 is linked to atherosclerosis.